摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4-bis((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,6,8,10,11,13-hexahydroxyphenanthro[1,10,9,8-opqra]perylene-7,14-dione | 1146629-10-8

中文名称
——
中文别名
——
英文名称
3,4-bis((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,6,8,10,11,13-hexahydroxyphenanthro[1,10,9,8-opqra]perylene-7,14-dione
英文别名
5,24-bis[(4-amino-2-oxopyrimidin-1-yl)methyl]-7,11,13,16,18,22-hexahydroxyoctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(26),2,4(25),5,7,10,12,14(28),15(27),16,18,21,23-tridecaene-9,20-dione
3,4-bis((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,6,8,10,11,13-hexahydroxyphenanthro[1,10,9,8-opqra]perylene-7,14-dione化学式
CAS
1146629-10-8
化学式
C38H22N6O10
mdl
——
分子量
722.627
InChiKey
YITANTQABOJFCC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    54
  • 可旋转键数:
    4
  • 环数:
    10.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    273
  • 氢给体数:
    8
  • 氢受体数:
    10

反应信息

  • 作为产物:
    描述:
    10,13-bis((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,3,4,6,8,15-hexahydroxydibenzo[a,o]perylene-7,16-dione乙醇丙酮 为溶剂, 反应 2.0h, 以88%的产率得到3,4-bis((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,6,8,10,11,13-hexahydroxyphenanthro[1,10,9,8-opqra]perylene-7,14-dione
    参考文献:
    名称:
    ω,ω′-Appended nucleo-base derivatives of hypericin
    摘要:
    omega,omega'-Disubstituted hypericin derivatives with the nucleo-bases thymine, cytosine, and adenine in these positions were prepared starting from tri-O-methyl-omega-bromoemodin. The most promising derivative proved to be that with a thymine moiety. It displayed the best solubility of the three products together with a potency to produce singlet oxygen and/or reactive oxygen species comparable to the parent compound hypericin. In addition, although no specific interaction with DNA or poly(2'-deoxyadenylic acid) could be detected, it proved to be significantly better accumulating in the nucleus of prostatic cancer LNCaP cells than hypericin making it a promising candidate for a second-generation photodynamic hypericin agent.
    DOI:
    10.1007/s00706-008-0898-0
点击查看最新优质反应信息